Rexahn Effects 1-for-12 Reverse Stock Split

NEXT STORY
Helping to Add Esophageal Adenocarcinoma to the List of Preventable Cancers
PREV STORY
FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tetraphase Pharmaceuticals to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases

author_avatar
NASDAQ Market News

RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit

author_avatar
NASDAQ Market News

Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress

author_avatar
NASDAQ Market News